Transforming Growth Factor Beta (Tgf-Beta) Inhibitor – Pipeline Review, 2020

Various clinical studies have demonstrated the role of TGF-Beta family in the development and progression of various conditions including cancer, bone remodeling, and muscular dystrophy among others. Transforming growth factor beta (TGF-Beta) inhibitors are molecules that inhibit the TGF-beta family members. The superfamily of TGF-Beta inhibitors have demonstrated various clinical applications by delaying cancer progression and preventing fibrosis. Various forms of these inhibitors including natural and other soluble forms including monoclonal antibodies are being developed.

TGF-Beta Inhibitor has shown immunosuppressive effects in the malignant tumor by inhibiting the immune cells from the tumors associated with breast cancer, prostate cancer, colon cancer, and basal cell cancer, etc. In 2019, according to the American Cancer Society (ACM), an estimated 268,600 new cases of invasive breast cancer were diagnosed in women globally.

With the growing prevalence of various cancer around the globe and the demand of effective treatment for cancer, various pharmaceutical companies along with various government-funded research organizations have been focusing on developing TGF-Beta Inhibitor molecules and studying the mechanisms of these inhibitory molecules that can be used to treat various cancers. For instance; AVID200 which is being studied by Forbius (Formation Biologics) is currently in phase-1 clinical trials for studying the ambition mechanism of TGFβ Inhibitor in patients with solid tumor malignancies

At present around 50% of the pipeline candidates for TGF-Beta Inhibitor are in the phase-3 stage. More than half of the studies are sponsored by industry.

Report Description

The report on ‘TGF-Beta Inhibitor – Pipeline Review, 2020’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for TGF-Beta Inhibitor. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as recent advances in R&D and current market scenario for TGF-Beta Inhibitor.

The report on ‘TGF-Beta Inhibitor – Pipeline Review, 2020, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for TGF-Beta Inhibitor


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for TGF-Beta Inhibitor


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary